Champions Oncology Inc (CSBR)vsBeiGene, Ltd. (ONC)
CSBR
Champions Oncology Inc
$5.10
+0.09%
HEALTHCARE · Cap: $70.98M
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 10214% more annual revenue ($6.13B vs $59.42M). ONC leads profitability with a 10.7% profit margin vs -2.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
CSBR
Avoid25
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.5%
Fair Value
$10.26
Current Price
$5.10
$5.16 discount
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Trading at 18.2x book value
Smaller company, higher risk/reward
Elevated debt levels
ROE of -53.3% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CSBR
Revenue growth of 12.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : CSBR
The primary concerns for CSBR are Price/Book, Market Cap, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
CSBR profiles as a turnaround stock while ONC is a growth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 25/100) and 29.6% revenue growth. CSBR offers better value entry with a 42.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Champions Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?